ADVFN - Advanced Financial Network.
HOME» NYSE » C » CVS Stock Price » CVS Stock News

Cvs Share News

 Cvs Caremark Corp. Stock Price
CVS Stock Price
 Cvs Caremark Corp. Stock Chart
CVS Stock Chart
 Cvs Caremark Corp. Stock News
CVS Stock News
 Cvs Caremark Corp. Company Information
CVS Company Information
 Cvs Caremark Corp. Stock Trades
CVS Stock Trades

CVS Caremark CEO Merlo's 2011 Pay Jumped 29% To $14.1 Million

By John Kell Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Total pay for CVS Caremark Corp.'s (CVS) chief executive and president, Larry J. Merlo, grew 29% to $14.1 million last year, according to a filing with the Securities and Exchange Commission. The drugstore retailer and pharmacy-benefits manager disclosed that Merlo's base salary, option awards and nonequity incentive-plan compensation all increased, while stock awards were lower. Merlo first joined the company in 1998 and has served in several executive roles, including chief operating officer and president of CVS/pharmacy. He took on his current roles a year ago. Chief Financial Officer Dave Denton's total pay jumped 35% to $4.6 million. Denton has been with CVS since 1999. Per Lofberg, president of CVS Caremark Pharmacy Services, saw his pay decline 55% to $7.1 million, as he joined CVS at the beginning of 2010 and was thus awarded a $1.5 million bonus and $7 million in stock awards during the prior-year period. President of CVS/pharmacy, Mark Cosby, joined CVS last September and was compensated $9.6 million last year. That figure includes a nearly $1.4 million bonus and over $7 million in stock and option awards. CVS's shares ended last year with a 17% gain, exceeding the broader market's growth as investors and analysts praised the company's integration of pharmacy-benefits manager Caremark. CVS has touted the success of its MinuteClinic retail health-care centers, and observers are banking on the retailer to benefit from the contract expiration between rival Walgreen Co. (WAG) and PBM Express Scripts Inc. (ESRX). CVS shares closed down 0.5% to $44.88 and were flat after hours. The stock is up 10% this year. -By John Kell, Dow Jones Newswires; 212-416-2480;

Stock News for Cvs (CVS)
11/23/201508:50:00CVS Chooses New Cholesterol Drug for Caremark
11/23/201508:29:00CVS Chooses Repatha as New Cholesterol Drug for Caremark
11/23/201508:05:00CVS/pharmacy Helps Shoppers Enjoy a Healthier, Less Stressful...
11/23/201508:00:00CVS Health Announces Formulary and Therapy Strategy for PCSK9...
11/21/201512:04:023 Healthcare Stocks You Don't Have to Babysit
11/18/201511:00:00CVS Health Achieves Perfect Score on 14th Annual Scorecard on...
11/18/201509:00:00CVS Health Introduces New Digital Pharmacy Tools to Help Make...
11/16/201508:30:00CVS Health Research Institute Study Demonstrates Impact of Prescription...
11/11/201509:34:02Walgreens Boots Alliance Inc. Awaits FTC Decision
11/10/201523:10:00Express Scripts Cuts Off Pharmacy That Sold Horizon Pharma Drugs
11/10/201519:43:00Leases to Put New Weight on Corporate Balance Sheets
11/10/201509:39:02Walgreens Boots Alliance's Buyout of Rite Aid Could Really Shake...
11/10/201509:00:00First MinuteClinic Walk-in Medical Clinics Open in Springfield...
11/09/201509:37:02Living With Leverage in Walgreens Boots Alliance's Acquisition...
11/07/201510:41:03Does Rite Aid's PBM Business Matter to Walgreens Boots Alliance...
11/06/201516:32:06Statement of Changes in Beneficial Ownership (4)
11/06/201516:30:39Statement of Changes in Beneficial Ownership (4)
11/06/201516:26:21Statement of Changes in Beneficial Ownership (4)
11/06/201516:19:34Statement of Changes in Beneficial Ownership (4)
11/06/201516:11:58Statement of Changes in Beneficial Ownership (4)

Cvs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations